Integrated BioPharma reports Q1 FY2023 net loss; revenue down 3.1% YoY

INTEGRATED BIOPHARMA INC

2023-Q1 EPS reported $0.00 revenue$12,326,000

Revenue $12.3M, down ~3.1% YoY from $12.8M.
Operating income $30K vs $585K; net loss $35K vs net income $516K.
Diluted EPS $0.00 per share vs $0.02 in prior-year quarter.
Co-CEOs cite customer overstocking from pandemic as reason for sales decline.
Two largest customers in Contract Manufacturing segment made up 85% of revenue (91% a year ago).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

INTEGRATED BIOPHARMA INC reported quarter ended September 30, 2022 results: revenue $12.3 million, net income net loss of approximately $35,000 or $0.00 per share, EPS $0.00 per share of common stock.

Period: quarter ended September 30, 2022
Revenue: $12.3 million
Net income: net loss of approximately $35,000 or $0.00 per share
EPS: $0.00 per share of common stock
Result: reported results

Exact text from the filing

Inc. (OTCQX: INBP) (the “Company” or “INBP”) reports its financial results for the quarter ended September 30, 2022. Revenue for the quarter ended September 30, 2022 was $12.3 million compared to $12.8 million for the quarter ended September 30, 2021, a decrease of $0.5 million or approximately 3.1%. The Company had operating income for the quarter ended

View on SEC.gov

Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-22-027367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.